tbuckley/cabot-search huggingface dataset:
P252Plasma osmolality predicts clinical outcome in patients with acute coronary syndrome undergoing percutaneous coronary intervention
Authors: M Rohla, MKF Freynhofer, IT Tentzeris, SF Farhan, JW Wojta, KH Huber, TWW Weiss
Journal: Cardiovascular Research (2014)

Aims: The impact of plasma osmolality on clinical outcome in acute coronary syndrome (ACS) patients has not been investigated so far. Methods and Results: In a retrospective analysis, we included 985 patients with ACS undergoing percutaneous coronary intervention (PCI). Plasma osmolality was calculated using concentrations of sodium, plasma glucose and blood urea nitrogen at admission. Patients were stratified by quartiles (Q) of admission osmolality, clinical outcome was compared between those groups. The primary endpoints were in-hospital, 30-day and one-year mortality. Univariate analysis in the Cox proportional-hazards model revealed significantly higher rates of in-hospital death for patients with osmolality in Q4, as compared to patients with osmolality in Q1-Q3 (HR 5.4, 95% CI 3.3;9.0, p<0.01). After adjustment for confounding baseline variables, osmolality in Q4 was associated with 2.8-fold hazard of in-hospital death (HR 2.75, 95% CI 1.35;5.61, p=0.005). Upon multivariate analysis, admission osmolality in Q4 vs. Q1-Q3 was associated with higher mortality rates after 30 days (HR 2.53, 95% CI 1.23;5.21, p=0.012) and one year (HR 1.73, 95% CI 1.02;2.91, p=0.04). Moreover, we performed landmark analysis in order to exclude critically ill patients, which revealed similar adjusted rates of death beyond 30 days to one year (HR 1.21; 95% CI 0.55;2.66, p=0.642). Conclusion: Using the 4th quartile of plasma osmolality at admission as a natural cut-off point, osmolality in Q4, as compared to Q1-Q3, was significantly predictive of short term, but not long-term outcome in ACS patients undergoing coronary stenting. Our data suggest osmolality to be an independent, feasible and cost-effective tool for rapid risk stratification in ACS patients.
TCTAP C-038 Insight from Serial Treatment with Excimer Laser, Scoring Balloon, Paclitaxel Coated Balloon for In-Stent Restenosis of Drug Eluting Stent
Authors: Tomohiko Watanabe, Daitarou Kanno, Yutaka Tadano, Ken Kobayashi, Yoshifumi Kashima, Tsutomu Fujita
Journal: Journal of the American College of Cardiology (2015)
IT-29 * IMMUNE CHECKPOINT BLOCKADE FOR GLIOBLASTOMA: PRECLINICAL ACTIVITY OF SINGLE AGENT AND COMBINATORIAL THERAPY
Authors: D. Reardon, P. Gokhale, K. Ligon, X. Liao, S. Rodig, J. Zhou, L. Qin, S. Hodi, K. Jones, A. Sauer, N. Kohl, G. Dranoff, G. Freeman
Journal: Neuro-Oncology (2014)

BACKGROUND: Outcome for glioblastoma (GBM) remains dismal and innovative treatment strategies are desperately needed. Growing data support the contribution of local and systemic immune checkpoint molecules mediating immunosuppression by GBM tumors. METHODS: Luciferized GL261 cells (GL261-Luc) were stereotactically implanted intracranially in albino C57BL/6 mice. Cohorts of mice with growing tumors (increasing bioluminescence) were treated with murine monoclonal antibodies (MAb) against PD-1, PD-L1, PD-L2, and CTLA-4 (single agent and combinations) every 3 days X 8 beginning 6 days following tumor implantation and were followed for overall survival. Subsets of mice underwent MRI as well as analysis of tumor infiltrating immune cells, and systemic immune cells and immunocytokines. Tumor re-challenge experiments were performed among long-term surviving mice. RESULTS: Immune checkpoint blockade was well tolerated with no apparent morbidity or mortality among treated animals. Improved survival was noted among mice treated with immune checkpoint blockade compared to appropriate controls. The most robust survival benefit was noted among mice treated with combinatorial therapy including 12/18 (75%) mice treated with anti-PD-1 + anti-CTLA-4 MAbs alive at 140 days with no evidence of residual tumor. MRI imaging among long-term surviving animals demonstrated clear evidence of initial tumor growth followed by regression and eradication of tumors. Long-term surviving mice appeared fully intact neurologically and exhibited no evidence of tumor growth following re-challenge of GL261-Luc cells injected subcutaneously. Characterization of tumor infiltrating immune cells as well as systemic immune cells and immunocytokines is ongoing. CONCLUSION: Immune checkpoint blockade provides significant survival benefit and appears safe in this immunocompetent, orthotopic syngeneic GBM model. Re-challenge experiments demonstrate evidence of long-term immunologic memory and further elucidation of underlying mechanisms of immune-mediated anti-tumor activity is ongoing. These data strongly support the evaluation of immune checkpoint inhibitors among patients with GBM.
AB0582 Traditional cardiovascular risk factors in psoriatic arthropathy. association with cardiovascular events.
Authors: G. Albert, M. Ricse, M. Aparicio, I. Martin, J. M. Nolla, J. Rodríguez
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Inflammatory diseases seem to be associated with increased cardiovascular risk in relation to the disease itself. In patients with psoriatic arthritis (PsA) there is evidence of increased morbidity and mortality related to cardiovascular risk factors (CVRF), both in the classical: smoking, hypertension, dyslipidemia, diabetes mellitus (DM), and obesity ; and non-conventional: CRP, fibrinogen and homocysteine. <h3>Objectives</h3> To determine the prevalence of classical cardiovascular risk factors in a series of PsA and determine its association with cardiovascular events. <h3>Methods</h3> Cross-sectional study of an observational controlled per protocol cohort in a rheumatology department of a university hospital, the study includes an observation period of 20 years (1992-2012). All patients fulfilled the CASPAR criteria. We included 226 patients who had been visited in 2012. We analyzed the demographic variables of disease, the variables traditionally associated with cardiovascular risk (BMI, hypertension, dyslipidemia, DM, smoking, blood lipid levels) and cardiovascular events recorded (ischemic heart disease, cerebral vascular accidents, arterial peripheral ischemia). Statistics: descriptive usual, ANOVA, chi-square, Fisher test, SPSS v.15. <h3>Results</h3> Of the 226 patients studied, 7.5% (17 patients) had had at least one cardiovascular event. We found a significant association (p &lt;0.05) with increasing age, male sex, history of DM, dyslipidemia, hypertension and BMI&gt; 25 (overweight and obesity), as well as higher levels of LDL cholesterol and triglycerides at the time the study. We found no association with active smoking, blood pressure, total cholesterol and HDL at the time of the study. <h3>Conclusions</h3> In our series of PsA the presence of classical cardiovascular risk factors were significantly associated with the prevalence of cardiovascular events. <h3>Disclosure of Interest</h3> None Declared
Twin Study Revives Debate Over Patient Protection
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Twin Study Revives Debate Over Patient Protection Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 19, 7 October 1992, Page 1469, https://doi.org/10.1093/jnci/84.19.1469 Published: 07 October 1992
P1169 EFFECT OF PEGYLATED INTERFERON OR RIBAVIRIN DOSE REDUCTION DURING TELAPREVIR BASED THERAPY ON SVR12 IN NULL-RESPONDERS AND RELAPSERS WITH ADVANCED LIVER FIBROSIS (ADVEX STUDY)
Authors: D. Zarebska-Michaluk, R. Flisiak, E. Janczewska, H. Berak, B. Dobracka, M. Librant-Suska, D. Kozielewicz, W. Lojewski, K. Jurczyk, T. Lapinski, J. Musialik, B. Postawa-Klosinska, J. Wroblewski, K. Augustyniak, M. Dudziak, I. Olszok, A. Ruszala, W. Kryczka, A. Pisula, A. Horban, W. Dobracki
Journal: Journal of Hepatology (2014)
224 TREATMENT BY INTRAOPERATIVE MICROWAVE ABLATION (MCN) ACHIEVED 70% OF 5-YEAR SURVIVAL RATE FOR HCC WITHIN MILAN CRITERIA: MCN AS AN ALTERNATIVE TO LIVER TRANSPLANTATION
Authors: Y. Takami, H. Saitsu, M. Tateishi, T. Ryu, Y. Wada
Journal: Journal of Hepatology (2012)
Scientists, Activists Discuss DES Issues
Authors: E. Blume
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Scientists, Activists Discuss DES Issues Get access Elaine Blume Elaine Blume Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 12, 17 June 1992, Pages 925–926, https://doi.org/10.1093/jnci/84.12.925 Published: 17 June 1992
P2-15-04: Clinical Significance of Resection with Curative Intent for Isolated Pulmonary Metastases from Breast Cancer. Multi-Institutional Study in Japan.
Authors: N Sato, S Ohsumi, T Iwase, H Inaji, M Mizutani, R Nishimura, H Mukai
Journal: Cancer Research (2011)

Abstract OBJECTIVE: Although resection of isolated pulmonary metastases is a common treatment in other primaries such as colon cancer, the role of lung metastasectomy of breast cancer is still unclear. The objective of the present study was to investigate the clinical outcome of our operated patients with isolated pulmonary breast cancer metastases and discuss the clinical implication of resection with curative intent for them. METHODS: We retrospectively analyzed 86 female patients with histologically proven isolated pulmonary metastases from breast cancer who were treated with surgery of curative intent between January 1980 and September 2010 at 7 Japanese hospitals. The mean age of them was 50 years, the median disease free interval (DFI) from the definitive surgery for the primary breast cancer was 4.6 years (range: 0.5−20.4 years) and the median follow-up after lung metastasectomy was 4.1 years (range: 0.3−30.9 years). RESULTS: Lung metastasectomy was performed by thoracotomy in 22 patients and by video-assisted thoracoscopic surgical resection in 64 patients. The number of metastatic foci resected was one for 79 patients, two for 6, and unknown for 1. Lymph node resection was performed for 12 patients, was not done for 69, and unknown for 5. Five-year survival rates after lung metastasectomy were 68% in the patients. The main prognostic factor was the DFI. Five-year survival rates for patients with DFI of longer than 2 years (n = 72) and those with DFI of shorter than 2 years (n=14) were 74.5% and 33.8%, respectively (p = 0.0006). Five-year survival rates after lung metastasectomy were 68% in patients without macroscopic residual pulmonary tumor after lung metastasectomy (n = 69) and 34% in those with macroscopic residual tumor (n = 12) (p = 0.023). Five-year disease free survival after lung metastasectomy for patients without macroscopic residual tumor was 51 %. Five-year survival rates were 78% in patient with endocrine hormonal therapy following lung metastasectomy (n = 51) and 53% in those without endocrine hormonal therapy (n = 35) (p = 0.045). No prognostic influence could be demonstrated for age, number of initial axillary node metastases, primary tumor size. CONCLUSION: The prognosis of the breast cancer patients with isolated pulmonary metastases who underwent metastasectomy with curative intent was good. It was affected by the biological aspects of the primary tumor, “curativity” of the resection, and systemic treatments after lung resection. It may be expected that some of those patients will be cured by surgery with curative intent. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-15-04.
SP0143 Ten Eular Recommendations for Use of Imaging in Spondyloarthritis Clinical Practice
Authors: L. Terslev
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> A task force convened by the European League Against Rheumatism (EULAR) comprising rheumatologists, radiologists and methodologists from 11 countries developed 10 recommendations, based on both evidence obtained through systemic literature reviews as well as expert opinion. The recommendations encompass the role of imaging in making a diagnosis of axial or peripheral spondyloarthritis (SpA), monitoring inflammation and damage, predicting outcome, response to treatment, and detecting spinal fractures and osteoporosis (OP). Selected aspects of the recommendations are given below (NOT all recommendations and NOT the exact wording, due to space constraints): conventional radiography (CR) of the sacroiliac joint (SIJ) is recommended as the first imaging method to diagnose sacroiliitis as part of axial SpA, while magnetic resonance imaging (MRI) is an alternative first imaging method in certain cases. Ultrasound (US) or MRI may be used to detect peripheral arthritis, tenosynovitis, bursitis and particularly peripheral enthesitis, which may support the diagnosis of SpA. MRI of the SIJ and/or spine may be used to assess and monitor disease activity, while CR of the SIJ and/or spine may be used for long-term monitoring of structural damage, particularly new bone formation in axial SpA. In patients with anklyosing spondylitis (AS) (not nonradiographic axial SpA), initial CRs of the lumbar and cervical spine are recommended to detect syndesmophytes, which are predictive of development of new syndesmophytes. MRI (vertebral corner inflammatory lesion) may also be used to predict development of new radiographic syndesmophytes. When spinal fracture in axial SpA is suspected, CR is the recommended initial imaging method. In axial SpA without radiographic syndesmophytes in the lumbar spine, OP should be assessed by dual-emission x-ray absorptiometry of the hip and spine. The SOR for each recommendation varied, but was generally very high (mean 8.9-9.5). Recommendations for future research were agreed by consensus following the presentation of the evidence obtained from the literature reviews. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6279
LB-002 Unravelling The Relationship Between Mucins And Mucolytic Bacteria During Intestinal Inflammation
Authors: E Thursby, D Kavanaugh, EH Crost, LE Tailford, P Gunning, M Tremelling, A Watson, N Juge
Journal: Gut (2014)

<h3>Introduction</h3> The epithelium in the human GI tract is coated in protective mucus, which acts as a key component of the intestinal barrier. In the colon, mucus consists of an inner, impenetrable and firmly attached layer, and an outer layer that provides a habitat for commensals. Mucins that make up mucus are decorated in a diverse array of O-glycans, providing both nutrients and attachment sites for microbes. Dysbiosis of the microbiota and alterations in mucin glycosylation are often associated with Inflammatory Bowel Disease (IBD). Whether these factors are causes or consequences of inflammation remains to be elucidated. <h3>Methods</h3> We are using a multidisciplinary approach to uncover the molecular mechanisms leading to loss of barrier function in IBD. These include the isolation and purification of mucins and bacteria from mucosal lavages of patients undergoing colonoscopy. Mucin glycosylation is analysed by lectin screening using immunohistochemistry, AgPAGE gradient gel electrophoresis, and atomic force microscopy (AFM). This will be complemented by detailed structural analysis by mass spectrometry and High Performance Anion Exchange Chromatography (HPAEC). The composition of specific mucin-degrading groups is analysed by qPCR, and will be complemented by 16S metagenomic sequencing of the total mucosa-associated bacterial population. <h3>Results</h3> Mucins were purified from mucosal lavage and visualised with AFM, revealing the presence of fibrous chains with contour lengths ranging from tens of nanometers to several microns. The binding specificity of various lectins was utilised in force spectroscopy measurements to assess the affinity of their cognate sugars at the molecular scale. Preliminary data indicates that this technique is a promising new approach which can be further utilised to explore the spatial distribution of glycans in human intestinal mucins and investigate differences in varying disease states. In parallel, bacterial DNA was extracted from mucosal lavages, and quantitative PCR carried out to analyse the composition of the mucosa-associated bacterial population. Preliminary qPCR analysis revealed a trend towards an altered microbial profile in patients with inflammation. <h3>Conclusion</h3> Dysbiosis of the microbiota and alterations in mucosal barrier are often associated with IBD. Deciphering whether these factors are causes or consequences of inflammation will impact on the choice of therapeutic intervention strategies. Assessing the changes in mucin-degrading bacteria and mucin glycosylation at the human mucosal surface will provide evidence-based strategies to select and/or design effective treatments to restore barrier function. <h3>Disclosure of Interest</h3> None Declared.
Abstract 2723: Host response to HMTV
Authors: Stella M. Melana, Mariana Fernandez-Cobo, Tania Marin, Teiko Nartey, Ana Lee, Herberth Moran, James F. Holland, Beatriz GT Pogo
Journal: Cancer Research (2011)

Abstract Work from our laboratory demonstrated the presence of retroviral sequences homologous to the mouse mammary tumor virus (MMTV) in a large proportion of human breast cancers. These observations have been confirmed by others. A 660 bp sequence of the MMTV env gene, with no significant homology to any viral or human sequence reported in the GenBank, has been found in 40% of the U.S. human breast cancers studied. This sequence is expressed in most of the env positive tumors, and is not detected in the normal breast tissue of patients with env positive carcinomas, indicating its exogenous origin. A complete provirus structure with 95% homology to MMTV has been described and designated as human mammary tumor virus (HMTV). Betaretroviral particles from primary cultures of breast cancer cells (MSSM) have been isolated and characterized. Virion RNA is more than 90% homologous to MMTV RNA and to the HMTV proviral DNA previously identified. To find out if these particles were infectious, co-culture experiments between MSSM cells and normal human epithelial breast cells, B and T human lymphocytes and human dendritic cells were performed. The results demonstrated that the recipient human cells became infected with HMTV. However, protein expression was only observed in 10-15% of the infected cells by FACS analysis suggesting the presence of an innate resistance to HMTV in human cells. We have then investigated whether human APOBEC and TRIM proteins are implicated in resistance to HMTV expression. The results indicated that APOBEC G and F, TRIM 5, 21 and 25 are all highly expressed in HMTV cells as measured by quantitative RT-PCR. Additional molecular changes seen in infected cells are disruption of the cytoskeleton and evidence for epithelial-mesenchymal transition (EMT). Since expression of an endogenous retrovirus (HERV-K) env gene has been reported to be upregulated in human breast cancers we have also investigated its expression in HMTV-infected cells, primary MSSM cells and breast tumors by quantitative RT PCR. The results indicated that in all instances where HMTV was present, expression of HERV-K (HML-2) was less than the control counterpart. In conclusion, HMTV is able to infect a variety of cells bringing about striking molecular changes. Whether these changes play a role in tumorigenesis remains to be shown. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2723. doi:10.1158/1538-7445.AM2011-2723
Prevalence of BRCA1/2 Mutations and Variants in a Southwest Hispanic Population.
Authors: L. Ballinger, A. Wallace, Z. Dayao, M. Royce
Journal: Cancer Research (2009)

Abstract Background: There have been a limited number of studies of BRCA mutations in U.S. Hispanics. Of those previously published, two common mutations have been identified, and estimates of their prevalence vary, depending on the population studied. North American Hispanics are a heterogeneous population, consisting of Mexican, Caribbean, Central and South American descent. Furthermore, each of these groups has a significant admixture of other racial and ethnic groups. A limitation of most published studies is that they do not differentiate between these ethnically and genetically diverse Hispanics. In New Mexico, there is a large but relatively homogeneous Hispanic population. Since the University of New Mexico Cancer Center (UNMCC), sees a socially and economically diverse group of patients, the demographics of its Hispanic patients are similar to those of the whole state. Herein, we describe the prevalence of specific mutations and variants in Hispanics from a clinic-based population.Materials and Methods: A chart review of all patients evaluated for hereditary breast cancer risk from 1/1/2005 through 5/30/2009 was conducted. Data collected included patient age, self-reported ethnicity (including, if known, area of ancestral origin), cancer status, family history, BRCA testing status, including method (comprehensive analysis, Ashkenazi panel, single site, and/or comprehensive rearrangement testing), and what, if any, BRCA mutations or variants were found.Results: BRCA testing was performed on 312 patients, 70 of whom identified as NM Hispanic. Another 24 patients were of other Hispanic origins, mainly Mexican. Approximately 30% of those identified as NM Hispanic tested positive for mutations, and most mutations were found in BRCA1. All variants of uncertain significance in this group were found in BRCA2. Approximately 20% of other Hispanics tested positive for mutations, but variants of uncertain significance comprised a higher percentage of the results. In New Mexican Hispanics, 47% tested positive for BRCA1 187delAG, and another 19% tested positive for BRCA1 deletion of exons 9-12, both of which are previously described in the Hispanic populations from southern California and Colorado.Discussion: Although we found a large proportion of previously described mutations in our Hispanic population, 34% had other mutations. In this group, no mutation was seen more than once, indicating the need to offer these patients comprehensive BRCA testing or a combination of founder mutations testing followed by comprehensive sequencing. As most of our patients, even those identified as “Other Hispanic” have Colonial Spanish origins (via Mexico), this data is likely not applicable to Hispanics with other admixtures or historic arrival in the New World, such as Hispanics from the Caribbean. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4077.